NOT KNOWN DETAILS ABOUT LINSITINIB

Thyroid eye disease (TED) therapy Tepezza – the best asset in Amgen's $26 billion takeover of Horizon in 2023 – may very well be going through competition from A better-to-dose option from Sling Therapeutics.Zeidan was Formerly the Main growth officer at Millendo Therapeutics and held numerous positions at Celgene and Novartis wherever he led